Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer.
Ten patients with metastatic breast cancer were treated with a combination of recombinant alpha-interferon and recombinant interleukin-2. The toxicity of treatment was considerable, including one death on therapy. No objective responses were seen.